Newsroom
Home > Newsroom
340B In The News
September 10, 2020
“The Federal Program That Keeps Insulin Prices High”
Middlemen pocket discounts while forcing patients, employers and Medicare to pay more.
340B In The News
August 23, 2020
“Trump order on drug prices restricts helpful program”
Congress should protect a program that helps provide medications to patients most in need.
340B In The News
July 28, 2020
“Trump 340B order targets clinics serving the poor”
Trump 340B order targets clinics serving the poor
340B In The News
July 24, 2020
“Trump issues drug pricing executive orders on 340B, outpatient drug pay”
President Donald Trump on Friday announced four executive orders to advance policies forcing community health centers that receive 340B drug discounts to cut patients' costs for Epi-Pens and insulin, tying Medicare payment for outpatient drugs to international prices, passing drugmaker rebates to patients and allowing personal drug importation.
340B In The News
July 21, 2020
“PBM-Owned Specialty Pharmacies Expand Their Role In – and Profits From – the 340B Program”
Last week, I documented that nearly half of U.S. pharmacies now participate in the 340B Drug Pricing Program. Below, we update our exclusive analysis of the biggest specialty pharmacies within 340B.
340B In The News
July 1, 2020
“Appeals court upholds nearly 30% payment cut to 340B hospitals”
A federal appeals court has ruled the Trump administration can install nearly 30% cuts to the 340B drug discount program.
340B In The News
June 4, 2020
“Congress Has no Clue About What’s Driving up Drug Prices”
A coalition of think tanks and health care organizations – dubbed Lower Drug Prices Now – just launched a campaign to promote price controls on coronavirus treatments in development. Several Democratic House leaders want such language included in future stimulus packages.
340B In The News
May 21, 2020
“Hospitals Are Gaming the 340B Drug Program”
The COVID-19 crisis has been a brutal lesson on the limitations of government action and imagination. The response, thus far, has been a ‘business as usual’ expansion of entitlements and interventions in an attempt for the government (programs, loans, direct payments, welfare, food assistance, etc.) to take the place of private sector activity. It has not worked.